New Treatment Options for Metastatic Non-Small Cell Lung Cancer and Gastrointestinal Cancer
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 5
Special Issue Editors
Interests: gastrointestinal cancer; metastasis; cancer therapy; tumor microenvironment
Special Issue Information
Dear Colleagues,
The treatment landscape of metastatic non-small cell lung cancer (NSCLC) and gastrointestinal (GI) cancer has changed dramatically in recent years. Targeted therapies, such as third-generation tyrosine kinase inhibitors (TKIs), have extended survival for patients with EGFR and other oncogenic drivers, with 5-year survival rates now exceeding 30% in select cases. Moreover, targeted therapy is highly effective in patients with HER2-positive gastric or gastroesophageal cancers. Meanwhile, immune checkpoint inhibitors (ICIs) have transformed treatment for cancer patients without actionable mutations, significantly improving outcomes over chemotherapy regimens in previously treated patients with lung cancer and gastrointestinal cancer, and increasing overall survival while achieving a higher response rate. Combining immunotherapy with targeted therapy or chemotherapy can enhance efficacy, and such regimens are increasingly used. Beyond these milestones, new strategies, including immunostimulatory agents, cancer vaccines, and adoptive T-cell therapies, are currently under active investigation. Yet, these innovations bring not only promise but complexity: immune-related adverse events, resistance mechanisms, and patient stratification based on biomarkers remain ongoing challenges. We aim to highlight these developments in the context of NSCLC and GI cancer treatment in this Special Issue.
Prof. Dr. Lydia Meder
Dr. Anna M. Dmitrieva
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer
- gastrointestinal cancer
- metastasis
- molecular mechanisms
- targeted therapy
- immunotherapy
- chemotherapy
- vaccines
- cancer treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
